February 2025 Tender Notification
Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2024/25 Invitation to Tender dated 31 October 2024.
Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceutical under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on the 12th of March 2025 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
Pharmac cannot list a product (and Pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link).
Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and Pharmacies cannot claim) without the correct Pharmacode.
- 28 February 2025 Tender Notification [PDF 272 KB]
2024/25 Tender – Principal Supply Status applies until 30 June 2028
Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule
The decisions were as follows:
1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
Date of subsidy change |
Principal Supply date |
|---|---|---|---|---|---|---|
|
Carbimazole |
Tab 5 mg; 100 tablet bottle pack |
$7.56 |
$7.56 |
Neo-Mercazole (AFT) |
1 July 2025 |
1 December 2025 |
|
Clopidogrel1 |
Tab 75 mg; 84 tablet blister pack |
$5.07 |
$5.07 |
Arrow-Clopid (Teva) |
1 July 2025 |
1 December 2025 |
|
Codeine phosphate |
Tab 15 mg; 100 tablet blister pack |
$5.92 |
$5.82 |
Noumed (Noumed) |
1 July 2025 |
1 December 2025 |
|
Codeine phosphate |
Tab 30 mg; 100 tablet blister pack |
$6.98 |
$6.88 |
Noumed (Noumed) |
1 July 2025 |
1 December 2025 |
|
Codeine phosphate |
Tab 60 mg; 100 tablet blister pack |
$13.89 |
$13.89 |
Noumed (Noumed) |
1 July 2025 |
1 December 2025 |
|
Diclofenac sodium |
Tab long-acting 75 mg; 100 tablet blister pack |
$19.60 |
$10.00 |
Voltaren SR (Novartis) |
1 April 2025 |
1 August 2025 |
|
Diltiazem hydrochloride |
Cap long-acting 120 mg; 500 capsule bottle pack |
$65.35 |
$65.35 |
Diltazem CD Clinect (Clinect) |
1 July 2025 |
1 December 2025 |
|
Emtricitabine with tenofovir disoproxil |
Tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a maleate); 30 tablet bottle pack |
$15.45 |
$13.45 |
Tenofovir Disproxil Emtricitabine Viatris (Viatris) |
1 July 2025 |
1 December 2025 |
|
Erythromycin (as lactobionate) |
Inj 1 g; 1 vial pack |
$10.00 |
$10.00 |
Erythrocin IV (AFT) |
1 July 2025 |
1 December 2025 |
|
Hydrocortisone |
Crm 1%; 500 g jar |
$20.40 |
$20.40 |
Noumed (Noumed) |
1 September 2025 |
1 February 2026 |
|
Mirtazapine |
Tab 30 mg; 30 tablet blister pack |
$2.60 |
$2.34 |
Noumed (Noumed) |
1 August 2025 |
1 January 2026 |
|
Mirtazapine |
Tab 45 mg; 30 tablet blister pack |
$3.45 |
$3.10 |
Noumed (Noumed) |
1 August 2025 |
1 January 2026 |
|
Oestradiol valerate |
Tab 1 mg; 84 tablet blister pack |
$12.36 |
$12.36 |
Progynova (Bayer) |
1 July 2025 |
1 December 2025 |
|
Oestradiol valerate |
Tab 2 mg; 84 tablet blister pack |
$12.36 |
$12.36 |
Progynova (Bayer) |
1 July 2025 |
1 December 2025 |
|
Pethidine hydrochloride |
Tab 50 mg; 10 tablet bottle pack |
$8.68 |
$8.68 |
Noumed Pethidine (Noumed) |
1 September 2025 |
1 February 2026 |
|
Sumatriptan1 |
Inj 12 mg per ml, 0.5 ml; 2 injection pack OP |
$29.80 |
$29.80 |
Clustran (Douglas) |
1 July 2025 |
1 December 2025 |
|
1This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 4 clause 2.3(c)(ii) of the 2024/25 Invitation to Tender. |
||||||
2. Tenders awarded to pharmaceuticals where at least one other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
Listing date |
Principal Supply date |
Currently listed brand (Supplier) (Pharmacode) to be delisted |
|---|---|---|---|---|---|---|---|
|
Hydrogen peroxide |
Crm 1%; 15 g tube OP |
$8.56 (per 10 g) |
$4.89 |
Crystaderm (AFT) |
1 August 2025 |
1 January 2026 |
Crystaderm (AFT) (2399504) |
|
Levomepromazine |
Inj 25 mg per ml, 1 ml; 10 glass ampoule pack |
$24.48 |
$23.26 |
Wockhardt (Max Health) |
1 July 2025 |
1 December 2025 |
Nozinan S29 (Max Health) (2501902) |
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.
3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
DV Limit |
Listing date |
Principal Supply date |
|---|---|---|---|---|---|---|---|
|
Carbimazole |
Tab 5 mg; 100 tablet bottle pack |
$7.56 |
$7.56 |
Neo-Mercazole (AFT) |
5% |
1 July 2025 |
1 December 2025 |
|
Clopidogrel2 |
Tab 75 mg; 84 tablet blister pack |
$5.07 |
$5.07 |
Arrow-Clopid (Teva) |
5% |
1 July 2025 |
1 December 2025 |
|
Codeine phosphate |
Tab 15 mg; 100 tablet blister pack |
$5.92 |
$5.82 |
Noumed (Noumed) |
5% |
1 July 2025 |
1 December 2025 |
|
Codeine phosphate |
Tab 30 mg; 100 tablet blister pack |
$6.98 |
$6.88 |
Noumed (Noumed) |
5% |
1 July 2025 |
1 December 2025 |
|
Codeine phosphate |
Tab 60 mg; 100 tablet blister pack |
$13.89 |
$13.89 |
Noumed (Noumed) |
5% |
1 July 2025 |
1 December 2025 |
|
Diclofenac sodium |
Tab long-acting 75 mg; 100 tablet blister pack |
$19.60 |
$10.00 |
Voltaren SR (Novartis) |
5% |
1 April 2025 |
1 August 2025 |
|
Diltiazem hydrochloride |
Cap long-acting 120 mg; 500 capsule bottle pack |
$65.35 |
$65.35 |
Diltazem CD Clinect (Clinect) |
5% |
1 July 2025 |
1 December 2025 |
|
Emtricitabine with tenofovir disoproxil |
Tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a maleate); 30 tablet bottle pack |
$15.45 |
$13.45 |
Tenofovir Disproxil Emtricitabine Viatris (Viatris) |
5% |
1 July 2025 |
1 December 2025 |
|
Erythromycin (as lactobionate) |
Inj 1 g; 1 vial pack |
$10.00 |
$10.00 |
Erythrocin IV (AFT) |
5% |
1 July 2025 |
1 December 2025 |
|
Hydrocortisone |
Crm 1%; 500 g jar |
$20.40 |
$20.40 |
Noumed (Noumed) |
5% |
1 September 2025 |
1 February 2026 |
|
Levomepromazine |
Inj 25 mg per ml, 1 ml; 10 glass ampoule pack |
$24.48 |
$23.26 |
Wockhardt (Max Health) |
5% |
1 July 2025 |
1 December 2025 |
|
Lidocaine [lignocaine] hydrochloride with adrenaline |
Inj 1% with adrenaline 1:100,000, 5 ml; 10 glass ampoule pack |
$32.00 |
$32.00 |
Xylocaine (Aspen) |
5% |
1 July 2025 |
1 December 2025 |
|
Mirtazapine |
Tab 30 mg; 30 tablet blister pack |
$2.60 |
$2.34 |
Noumed (Noumed) |
5% |
1 August 2025 |
1 January 2026 |
|
Mirtazapine |
Tab 45 mg; 30 tablet blister pack |
$3.45 |
$3.10 |
Noumed (Noumed) |
5% |
1 August 2025 |
1 January 2026 |
|
Oestradiol valerate |
Tab 1 mg; 84 tablet blister pack |
$12.36 |
$12.36 |
Progynova (Bayer) |
5% |
1 July 2025 |
1 December 2025 |
|
Oestradiol valerate |
Tab 2 mg; 84 tablet blister pack |
$12.36 |
$12.36 |
Progynova (Bayer) |
5% |
1 July 2025 |
1 December 2025 |
|
Pethidine hydrochloride |
Tab 50 mg; 10 tablet bottle pack |
$8.68 |
$8.68 |
Noumed Pethidine (Noumed) |
5% |
1 September 2025 |
1 February 2026 |
|
Sumatriptan2 |
Inj 12 mg per ml, 0.5 ml; 2 injection pack |
$29.80 |
$29.80 |
Clustran (Douglas) |
5% |
1 July 2025 |
1 December 2025 |
|
2This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 4 clause 2.3(c)(ii) of the 2024/25 Invitation to Tender. |
|||||||
4. Tenders awarded to pharmaceuticals where at least one other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
DV Limit |
Listing date |
Principal Supply date |
Currently listed brand (Supplier) (Pharmacode) to be delisted |
|---|---|---|---|---|---|---|---|---|
|
Hydrogen peroxide |
Crm 1%; 15 g tube |
$8.56 (per 10 g) |
$4.89 |
Crystaderm (AFT) |
5% |
1 August 2025 |
1 January 2026 |
Crystaderm (AFT) (2399504) |
Tender declines – Products where no tender is to be awarded for Principal Supply Status
Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2022/23 Invitation to Tender, dated 31 October 2022.
|
Chemical Name |
Line Item |
|---|---|
|
Temozolomide |
Cap 5 mg |
|
Temozolomide |
Cap 20 mg |
|
Temozolomide |
Cap 100 mg |
|
Temozolomide |
Cap 140 mg |
|
Temozolomide |
Cap 250 mg |
Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2024/25 Invitation to Tender, dated 31 October 2024.
|
Chemical Name |
Line Item |
|---|---|
|
Alfacalcidol |
Cap 0.25 mg |
|
Alfacalcidol |
Cap 1 mg |
|
Alfacalcidol |
Oral drops 2 mcg per ml |
|
Caffeine citrate |
Inj 20 mg per ml (caffeine 10 mg per ml) |
|
Caffeine citrate |
Oral liq 20 mg er ml (10 mg base per ml) |
|
Methylphenidate hydrochloride (current access) |
Cap modified release 10 mg |
|
Methylphenidate hydrochloride (current access) |
Cap modified release 20 mg |
|
Methylphenidate hydrochloride (current access) |
Cap modified release 30 mg |
|
Methylphenidate hydrochloride (current access) |
Cap modified release 40 mg |
|
Methylphenidate hydrochloride (widened access) |
Cap modified release 10 mg |
|
Methylphenidate hydrochloride (widened access) |
Cap modified release 20 mg |
|
Methylphenidate hydrochloride (widened access) |
Cap modified release 30 mg |
|
Methylphenidate hydrochloride (widened access) |
Cap modified release 40 mg |
|
Nifedipine |
Tab long acting 10 mg |
|
Nifedipine |
Tab long acting 20 mg |
|
Nifedipine |
Tab long acting 30 mg |
|
Nifedipine |
Tab long acting 40 mg |
|
Perindopril with amlodipine |
Tab perindopril arginine 10 mg with amlodipine 10 mg |
|
Perindopril with amlodipine |
Tab perindopril arginine 10 mg with amlodipine 5 mg |
|
Perindopril with amlodipine |
Tab perindopril arginine 5 mg with amlodipine 10 mg |
|
Perindopril with amlodipine |
Tab perindopril arginine 5 mg with amlodipine 5 mg |
For products included in the 2022/23, 2023/24 and 2024/25 Invitation to Tender where no announcement has yet been made, a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.